Background: Cervical cancer (CC) remains a leading cause of gynaecological cancer-related mortality worldwide. CC pathogenesis is triggered when human papillomavirus (HPV) inserts into the genome, resulting in tumour suppressor gene inactivation and oncogene activation. Collecting tumour and blood samples is critical for identifying these genetic alterations.
Nonetheless, some recent drugs, particularly when used in combination, showed promising results in selected cancers (Furue and Kadono, 2016) . Many precision medicine trials are currently ongoing; they involve (1) the addition of targeted therapies to standard therapies according to specific single molecular alterations and/or tumour types and (2) algorithm testing in late-stage tumour types . The latter programs imply well-defined biobanking procedures for tumour, blood, sera and blood collection a prerequisite for precise and reproducible molecular results. Feedback on prospective biobanking experiences and challenges are starting to be reported with relevant standard operating procedures (SOPs; Diaz et al, 2013; Riondino et al, 2015) . Results, available from the prospective 'SHIVA' trial conducted at the Institut Curie, turned out negative for the primary endpoint. Single drug usage in advanced disease is thought to be a reason for this overall negative result. However, it was concluded that administration of targeted therapies in latestage patients, used outside of their usual indications, might still be a valid approach to prolonging disease-free survival in subgroups of patients, in particular those harbouring a molecular alteration in the MEK/RAF signalling pathway .
We have focused on CC, where biopsies can be easily obtained. Molecular studies of CC are relevant for evaluating cancer pathogenesis as a dynamic multistep process that includes continuous genetic diversification, clonal expansion and selection. Essential genetic alterations in CC (and to 1/3 of HNSCC) are virtually always kicked off by the insertion of pathogenic HPVs leading to abnormal activation of oncogenes and/or the inactivation of tumour suppressor genes. These alterations can be detected using a range of techniques (Le Tourneau et al, 2016) . The International Cancer Genome Consortium (ICGC) studied more than 25 000 cancer genomes from patients with 50 different cancer types and identified the most frequent gene copy number variations, translocations, and point mutations to determine those that can be considered 'druggable' therapeutic targets (International Cancer Genome et al, 2010) . When we started this clinical trial, no prospective data set studying the relevance of molecular alterations in CC outcome was available.
Owing to the well-known high intra-tumour heterogeneity of genetic alterations, there have been few recent clinical breakthroughs in any cancer. It has been suggested that neo-antigens, which potentially influence immune surveillance, may arise in parallel with genetic alterations (Marusyk et al, 2012; McGranahan et al, 2016) , presenting opportunities for immunological targeting. Although treatment using molecular stratifications has not been attempted systematically in CC, differential mutational and gene expression patterns are associated with squamous or adenocarcinoma CC histopathological types (Schwarz et al, 2012; Scholl et al, 2013; Jimenez-Wences et al, 2014; Ojesina et al, 2014; Rusan et al, 2015; Spaans et al, 2015) . In retrospective data sets of CC and head and neck tumours combined, three subgroups of pathway alterations were revealed in human papillomavirus (HPV)-associated cancer: namely cell proliferation/survival, immune response/cell death, and cellular differentiation (Rusan et al, 2015) .
BIO-RAIDs, a prospective study of patients with previously non-treated CC (stages IB1-IV), was initiated in seven European countries with the aim of analysing primary tumours at the molecular level along with patient outcome to stratify tumours into classes according to the underlying pathway activation and prognosis. Preliminary bioinformatics analysis using ACSN (Atlas of Cancer Signalling Networks), which was based on TCGA, Ojesina (Ojesina et al, 2014) and the first exome sequencing data from the first 48 BIO-RAIDs patients, suggested that CC can be stratified into 5 classes with distinct molecular features (unpublished data) . At the time of manuscript submission, BIO-RAIDs had recruited over 400 patients. The BIO-RAIDs protocol was published previously (Ngo et al, 2015) .
Here we present the challenges for molecular assessment studies that were identified during this systematic biobanking and provide recommendations for conducting similar studies in the future. The identified challenges were related to: diversity of legal and ethical standards in different countries, lack of clinical trial resources at some centres, lack of experience in biobanking in many centres, and to the complexity integrating molecular data on multiple samples (Figure 1 ). Clear guidelines are needed to perform a coherent and reproducible molecular analysis of tumours and to guide appropriate clinical trials. Our hope is that BIO-RAIDs will set the stage for future precision medicine studies by international groups.
CHALLENGES AND SUGGESTED RECOMMENDATIONS FOR FUTURE BIOBANKING STUDIES
Delays in regulatory approval before the initiation of clinical trials. One of the major challenges encountered was that the study protocol was perceived differently by the participating European countries, and variations in regulatory aspects in the countries involved complicated the initiation of the clinical trial (Table 1) . In some countries, BIO-RAIDs was considered an interventional study due to the request for iterative biopsies and blood sampling. In contrast, other countries considered it a non-interventional study since it did not modify standard treatment procedures. This classification impacted insurance fees and caused delays in contracting. Furthermore, in some countries, any biobanking study requires clinical study insurance, regardless of whether it is labelled 'interventional'. Insurance costs vary according to the number of patients, the risk of participating in the study, and protocol timelines. The variations in insurance fees were quite large, despite leverage between insurance agencies, and in particular the costs depended on whether the insurer had to insure patients outside of his home country. The timelines for contract negotiation between Sponsors (or Sponsor Delegates) and the different clinical sites depended on approval by the Boards of Directors of the hospitals involved. Protracted discussions about the types of responsibilities that were delegated to Sponsors or Sponsor Delegates included a detailed scrutiny of all monitoring tasks to minimise personmonths and therefore costs. One issue was the definition of the lieu to settle disputes in court and the absence of an established international rule concerning this matter. For BIO-RAIDs, it was decided that any dispute would be settled in accordance with the national law in the defendant's country. Lengthy procedures for reimbursing subcontracted tasks by administrations in highincome countries to contract research organisations in lowerincome countries were discouraging for both the clinical investigators and for the subcontracted support structures.
Recommendations for speeding up clinical trial initiation. Clearer European guidelines and common legislation would be helpful for future prospective studies that are 'without an experimental drug'. The new European regulation, European Union (EU) No. 536/2014, provides some modified regulatory requirements for low-interventional trials. Similar directives are urgently needed for biobanking studies which have minimal or no added risk for the patients. Sampling and biobanking are routine procedures in qualified hospitals and might ideally be part of the institutional coverage. The need for additional insurance for biobanking leading to targeted therapy trials should be examined further. Standard European guidelines for contracting between partners in clinical trials would be advantageous. Both operational and financial autonomy for heads of clinical support structures in larger hospitals/scientific administrations is important to expedite the implementation of new trials and reduce the time-to-site initiation.
Site-specific logistics in different European countries. Routine biobanking with clinical annotation and SOPs for tissue handling is relatively new for most sites, and takes time to set-up and to make it efficient (Table 2) . BIO-RAIDs identified the following issues that might cause delays: site-specific logistics; organisational issues, such as the availability of experienced investigational personnel; access to liquid nitrogen, and sampling logistics; and the quite variable experience of each site in terms of conducting clinical trials. In some countries, imaging procedures for staging, such as MRI, mandatory to assess a primary endpoint of response to standard therapy were not routinely available. The lack of cohesion between regional and national requirements for imaging type (CT rather than MRI) at some sites became apparent when the BIO-RAIDs study began.
Recommendations for improving site-specific logistics. Although an evaluation of study feasibility must focus on the availability of dedicated management personnel who can coordinate logistics and facilitate local management of the study, it must also investigate sites that have a high patient recruitment potential but few or absent dedicated management personnel. We recommend that sites strive to hire experienced management staff in sufficient numbers and train local staff. If this cannot be achieved, regardless of the reasons, the site should be barred from participation until its issues can be resolved. Site performance is also largely dependent on the principal investigator's (PI's) dedication and availability. If the PI moves to a different workplace or is unavailable for a protracted time, it can jeopardise patient recruitment and the ability of the site to conduct the study. Both the PI and an actively participating proxy should be involved in the trial from the start. If biobanking with clinical annotation is new or relatively new to a site that is otherwise experienced in clinical trial conduct, we advise sending experienced staff to the specific site to assist with the initial set-up and to provide tools for handling biobanking. Finally, international TripAdvisor-like public ratings of site performance might help facilitate necessary changes and improvements.
Collection and monitoring of clinical data and samples. A number of prognostic factors have been put forward for CC (Monk et al, 2007; Rose et al, 2015; Pelkofski et al, 2016) , virtually all data have been identified retrospectively, often from small patient populations (Table 3 ). The prospective assessment of prognosis allowing the comparison of lifestyle and clinical parameters with molecular patterns and outcome is of great interest to clinicians. This prompted us to develop an electronic case report form (eCRF) that required a major effort from clinicians and clinical trial investigators to (a) gather and fill in the data and (b) to control the data in source documents. Our initial version of the eCRF turned out not to be sufficiently user friendly for clinicians and clinical monitoring personnel and needed to be simplified.
In an attempt to reduce shipping costs, barcoded samples were sent in small batches to national referral centres, reviewed for missing samples and sent on in larger batches to the reference laboratory.
With over 400 patients registered at the time of submission, more than 5000 samples consisting of tumour (fixed and frozen) at baseline (and in case of residual tumour or progressive disease secondary biopsies at a later stage) together with whole blood, serum (baseline, post treatment, and 6 monthly) have been at this point transferred to a centralised laboratory at Erasmus, Rotterdam for quality control (QC). QC reviewed pathological diagnosis and evaluated tumour cellularity (430% for full exome, 10-30% for targeted panel) from the first and last slice of each set of tissue slices sent for molecular assessment.
All errors which occurred were human errors, the most serious one being a mislabelling by the carrier company, sending a batch to the wrong country. The late recognition of errors (inversion of labels for blood and serum) proved labour-intensive to correct. A central integration platform in knowledge data integration (KDI) at Institut Curie continuously checks for incoherences in the data, sending out reports to all laboratories and clinical monitoring groups. Incoherence in sample ID is checked first. The EAN-13 barcoding scheme was used for sample labelling in the BIO-RAIDS study. Although this format includes a built-in error-checking capability, it could only code for numeric values. Thus, when these barcoded sample IDs are imported into spreadsheet software such as Libre Office or Microsoft Office or into the R statistical computing environment, the 13 digit barcodes are routinely recognised as huge numeric values and are transformed into floating point numbers (for instance, 9110351350145 may be converted to 9.110351e þ 12 on import). Although it is possible to circumvent this ID corruption in all of the relevant software products, the import of EAN-13 barcodes that only contains digits still requires special attention. Data import issues related to the EAN-13 barcodes can easily be avoided by using both letters and digits. Such 'import-safe' barcodes require appropriate symbology, for example, code 128 that can encode all 128 ASCII characters while offering a built-in checksum system similar to that of EAN-13.
Incoherencies in sample preparation (fixed instead of frozen) or tissue type (tumour, formalin-fixed paraffin-embedded (FFPE), and serum) could be corrected by inspection since the colour of the material in the tube allows to distinguish between FFPE fixed tumour and serum; equally blood and serum are distinguishable by inspection. We implemented a monthly report allowing highlighting the incoherences and making the necessary corrections. The only way to control the biobanking common information was to cross-check the biobanking annotations of sample ID and data of sampling used in each platform against information received from Erasmus and Quanticsoft.
Recommendations for timely sampling and for controlling sampling logistics and clinical data. For effective biobanking (that is, sample handling, shipping, and storage), we feel that sample sets from each patient should ideally be sent promptly to a fully accredited central biobank that will check that the sample is present and send a feedback on the quality of each sample in real time. The biobank should send out electronic alerts to centres when repeat sampling procedures are coming up with copies to the clinical monitoring personnel. Yet this needs to be cautiously evaluated in terms of costs.
Clinical data collection and monitoring tasks can be simplified if we adhere to the following principles. First, the data to be collected should be limited to data relevant for evaluating the study objectives. Second, the data should be captured in real time using a validated, user friendly eCRF to facilitate flawless data collection and integration. Third, the accuracy, completeness, and coherence of the entered data should be assured through eCRF internal controls. This allows a considerable reduction in on-site monitoring time and therefore a reduction in monitoring costs. The eCRF should include an interactive biobanking section that is accessible to and completed by the clinical centres as well as by the central molecular laboratories to ensure traceability and future use of samples in subsequent ancillary studies. WEBTRIAL was used for the BIO-RAIDs study. Many other easy-to-use eCRF backbones are available today, such as Marvin, REDcap, which is a free, webbased, user friendly electronic data capture (EDC) tool for research studies. The monitoring strategy should ideally be described in the monitoring plan, and significant steps that are meant to reduce the cost of monitoring should be considered. It is currently estimated that the use of complete source data verification will not necessarily result in a substantial improvement in study data. Rather, a riskbased approach for QC, including on-site monitoring, should focus on the study procedures and data, which are relevant for patient safety and data integrity. The following suggestions by Messenger et al (2012) might be worth exploring further: (1) issue a QC report for the data; (2) have a set of internal quality-assurance controls embedded in the eCRF; and (3) institute a yearly data audit programme that includes biobanking information that can be applied to non-interventional studies. Finally, the QC and monitoring strategies should be discussed initially with all participating partners, for example, with clinicians, data management personnel, and biostatisticians.
Optimal sampling and choice of molecular technologies Sampling procedures. A variety of challenges are associated with the molecular screening of solid tumours, the first being the collection of adequate samples for the selected molecular technique which dictates the specific handling of tissue samples (Table 4) . Cervical tumours are generally easier to access than other cancers, but it should be kept in mind that all biopsies are just a fragment of an observed lesion. Therefore a single tumour biopsy sample is likely to grossly underestimate intra-tumour heterogeneity (Gerlinger et al, 2012; Swanton, 2012 far more practical technique for routine clinical use, and WES has been incorporated into patient selection strategies in clinical trials (Roychowdhury and Chinnaiyan, 2014; Beltran et al, 2015) . WES was selected for use in the BIO-RAIDs study (n ¼ 100) to prospectively evaluate very diverse alterations, ranging from point mutations to whole chromosomal rearrangements, and to detect less frequent alterations that are relevant to patient outcome. BIORAIDs is developing targeted exome sequencing of a panel of genes that were chosen because they harbour hotspot mutations according to both our own WES data and according to the literature. Such a targeted panel offers several advantages; in particular, it is cost-and time-effective, and it has manageable bioinformatics and computational requirements (Roychowdhury and Chinnaiyan, 2014; Dietel et al, 2015) . Sequencing instruments, library preparation kits, sequence kits, and analytical tools are in constant development and are likely to change during the course of a multi-year study. For example, the Solid platform, which was the platform of choice during early BIO-RAIDs discussions, had become obsolete by the time the first patient samples were available. Thus, a series of adaptations had to be made to the technical platform. In addition, once the migration to the HiSeq Sequencing Systems was complete, Illumina released a novel sequencing chemistry, V4, that could handle more sequences per run and that had a longer read length. However, detailed QC assessment later revealed that the 125-bp V4 reads tended to show a sharp drop in sequencing quality in the last 10-15-bp regions, while the 100-bp reads using the previous V3 chemistry were much less affected by this phenomenon. The effect of the drop in the quality of V4 reads on the downstream analyses (such as somatic variant calling, copy number estimations) is still under investigation and requires changes in the computational pipelines.
Proteomics studies are needed to assess the functional relevance of mutated genes that are identified by genomics technologies. Proteins are highly dynamic molecules and are subject to extensive functional regulation, most notably by post-translational modifications. In-depth studies of proteomic profiles will help us understand CC tumour pathogenesis more comprehensively and could lead to the identification of novel biomarkers and cancer therapy targets (Sallam, 2015) . RPPA is a high-throughput dot-blot technology with two major advantages: first, it compares hundreds of biopsies simultaneously on the same array; second, it requires only small amounts of tissue. RPPA is therefore currently the method of choice for retrospective targeted analysis of biopsies. However, it is less well suited for prospective patient investigation for clinical decision-making. Furthermore, RPPA technology is targeted and therefore relies on the availability of high-quality antibodies. The percentage of tumour cells in the tissue is also a real issue. Laser capture microdissection can be used to enrich tumour regions, but this is time-consuming and substantially reduces the throughput. Finally, since post-translational modification is highly dynamic and unstable, the freezing, storage, and shipment conditions must be carefully controlled.
Immunohistochemistry provides a robust view of intra-tumour heterogeneity and is crucial for confirming the genomic alterations that are identified during genomic analyses. Furthermore, IHC is useful for studying the interactions between tumour cells and the host immune system. Unfortunately, standard chromogenic IHC has inter-assay variability, so quantifying the results is difficult. The main hurdle associated with IHC is linked to sample processing in that the tissue must be adequately fixed in formalin. In addition, standard IHC techniques are limited to the use of one specific antibody of interest, and different laboratories use different antibody clones.
Recommendations for tumour sampling and molecular techniques. One key issue in the selection of the best analytical technique is the availability of the appropriate type of sample, that is, tumour (fresh, frozen, or fixed), blood, or plasma.
Analysing multiple tumour biopsies from different sites is ideal, but can be logistically challenging. To ensure best quality sample for nucleic acid extraction procedures, one or more samples must be snap-frozen in liquid nitrogen and stored until analysis. The other samples must be quickly fixed in neutral-buffered formalin for pathological and molecular analyses. The aim should be to keep a mirror FFPE tumour block of the tumour area from which a frozen sample has been taken. Furthermore, a frozen sample of peri-tumoural normal tissue should also be obtained.
Molecular results are used to make treatment decisions and, consequently, are subject to legal obligations that are designed so that the tests are reproducible and adhere to high standards ensuring sensitivity and specificity. Molecular platforms therefore need to be validated. Despite the lack of clear guidelines, FDAcertified platforms in the USA and ISO-certified platforms in Europe are being developed (McShane et al, 2013) .
To minimise the risk of technical bias in the data set, it is highly desirable that every sample be processed using exactly the same kits and methods. If the logistics and the project timing allows it, and if the necessary instruments are available, it seems worthwhile to first gradually collect the complete set of qualitycontrolled DNA/RNA samples and then later to process them all within a single wet lab project to ensure identical kit versions for all of the analyses.
NGS or targeted digital PCR of cfDNA can be used to identify changes in the tumour mutational landscape, and cfDNA can be detected in the absence of CTCs (Bettegowda et al, 2014) . Targeted sequencing of cfDNA can detect driver mutations at low allele frequencies with high sensitivity (Frenel et al, 2015) . Such findings could allow treatment monitoring and early detection of resistant mutations before radiological signs of disease progression (Oxnard et al, 2014) . Notably, cfDNA can also be detected in other body fluids, like saliva and urine (Janku et al, 2014; Wang et al, 2015) . Using NGS to detect circulating cfDNA, it is possible to indirectly track tumour progression; moreover, mutations that were identified in the tumour can be detected with a simple blood sample (Lebofsky et al, 2015; Lianos et al, 2015) . Since cfDNA can originate from either the primary tumour or from a metastatic site, it serves as a 'liquid biopsy' that reflects the genetic heterogeneity of a patient and could potentially identify putative targets for therapy. cfDNA also represents a way to monitor genetic heterogeneity during treatment in a non-invasive manner. A recent paper supports this, describing how diverse cancers show detectable ctDNA alterations, with the majority being theoretically actionable by approved agents (Schwaederle et al, 2016) .
To reliably analyse protein modifications, the biopsy must be flash-frozen in liquid nitrogen, ideally on-site at each clinical centre. When there is no high-quality antibody available for a protein of interest, a protein downstream in the same signalling pathway can be utilised as a surrogate marker. Epithelial cell and immune cell infiltrate markers can be added to the analysis and might give a rough estimation of tumour content that can be compared with the pathology results. In the future, other technologies that overcome the difficulties of RPPA might be sufficiently improved and affordable that they could be used in clinical studies. Notably, rapid advances are being made in the field of mass spectrometry, but data interpretation remains a challenge, and large amounts of tissue are required to analyse the phosphoproteome.
For IHC analyses, the development of technical SOPs, the use of validated antibody clones, and specifically the use of (semi-) automated systems will enable quantitative pathology assessments. This field is currently taking a huge leap forward due to advances in digital pathology and due to the rapid development of simultaneous multispectral analysis of many different markers in one small biopsy, which will ultimately lead to its implementation in day-to-day pathology practice (Feng et al, 2015) . Therefore, objective, high-throughput biomarker quantification and co-localisation using multiplexed IHC will aid in the future selection of patients that might benefit from specific treatment (Huang et al, 2013; Dixon et al, 2015) .
Challenges in QC, data integration, and data analysis. Rapid advances in technology have decreased costs and improved throughput, allowing the collection of vast amounts of 'omics' information in cancer (Table 5 ). However, robust and reproducible bioinformatics tools that can be used to interpret these data are still being developed. NGS has paved the way for precision medicine in the field of oncology. The lower laboratory sequencing costs of NGS caused an exponential increase in the amount of data produced, putting a large strain on data managers and bioinformatics engineers who were called on to manage all of this information (Simon and Roychowdhury, 2013) . Collectively, NGS and 'omics' techniques have huge potential for clinical applications, but the techniques and tools are constantly developing. The availability of high-throughput technologies dedicated to clinical applications makes them very attractive for daily use in cancer centres. However, establishing these clinical facilities is not a trivial task due to the overwhelming amount of data. There are three challenges in extracting most of the relevant biological and clinical information from these data: (1) developing sufficiently powerful computational architecture (software/hardware); (2) establishing the organisational and management structure that is needed to define the procedures for collecting high-quality data that is reliable and traceable; and (3) developing scientific expertise to create sophisticated mathematical models that can predict the evolution of the disease and the risks to the patient (Barillot et al, 2012) .
Bioinformatics data analysis and recommendations for future clinical data architecture. Clearly efficient informatics and bioinformatics architecture is needed to support precision medicine to record, manage, and analyse all of the collected information. The architecture must also allow queries and the easy retrieval of data that might be useful, either now or in the future, for real-time therapeutic decisions so that clinicians can propose tailored therapy to the patient without delays. Accordingly, bioinformatics is among the most important bottlenecks in the routine application of precision medicine. Several challenges must be overcome to make precision medicine a reality. First, a seamless information system must be developed that allows data integration, data traceability, and knowledge sharing across the different stakeholders. Second, bioinformatics pipelines need to be developed to make relevant biological information from the highthroughput molecular profiles of the patient rapidly available to clinicians. Third, the architecture must ensure the reproducibility of the results. All of these bioinformatics challenges were reviewed by Servant et al (2014) . At the Institut Curie, in the context of the RAIDs project, a information system termed KDI (for 'knowledge and data integration') was set-up to ensure the sharing of information between partners, cross-software interoperability, automatic data extraction, and secure data transfer. Other similar systems are available today, such as the tranSMART platform, which is an open-source, community-driven knowledge management platform for translational medicine (Barash et al, 2015) .
CONCLUSION
In the era of precision medicine the numbers of biobanking studies are increasing and raise several issues. The BIO-RAIDs study identified challenges associated with the practical aspects of systematic biobanking that lead to delays in clinical trial initiation. To address these challenges, there needs to be increased cooperation and standardisation in terms of regulatory rules and practices across the EU. Although most errors are human errors and related to initial handling, there is a need for teaching courses for best-practice biobanking techniques standards and QC aspects. On another level there is a need for a better understanding by clinicians and by drug manufacturers of the technical and bioinformatics analytical skills needed to improve decision-making in the field of precision medicine. Although BIO-RAIDs is purely an analytical trial, it sets the stage for future clinical trials of specifically targeted drugs or drug cocktails. Ongoing work on cell lines that compares mutational and proteomics data with pharmacological profiling should help identify common targeted drugs and drug cocktails that benefit patients. In addition to these technical and clinical research aspects, the perception of patients and their feedback on biobanking is key. A recent study shows that patients are receptive to donate tissue samples if they are educated on the importance of specimen based research (Braun et al, 2014) , an observation that seems to be shared in the BioRaids population. 
